Get the Stockscreener App
42.90
1.76%
0.743
After Hours:
42.95
0.047
+0.11%
Mineralys Therapeutics Inc stock is traded at $42.90, with a volume of 1.66M.
It is up +1.76% in the last 24 hours and up +15.64% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$42.16
Open:
$42
24h Volume:
1.66M
Relative Volume:
1.08
Market Cap:
$2.84B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-15.72
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+12.87%
1M Performance:
+15.64%
6M Performance:
+220.17%
1Y Performance:
+216.39%
1-Day Range:
$41.01
$43.88
1-Week Range:
$35.31
$43.88
52-Week Range:
$8.241
$43.88
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
42.90 | 3.27B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Real time pattern detection on Mineralys Therapeutics Inc. stockJuly 2025 Trade Ideas & Daily Risk Controlled Trade Plans - newser.com
Applying big data sentiment scoring on Mineralys Therapeutics Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - newser.com
How to use Fibonacci retracement on Mineralys Therapeutics Inc.Earnings Summary Report & Consistent Income Trade Recommendations - newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explainedIndex Update & Free Low Drawdown Momentum Trade Ideas - newser.com
Published on: 2025-10-13 08:29:11 - newser.com
Can machine learning forecast Mineralys Therapeutics Inc. recoveryPortfolio Profit Report & Smart Allocation Stock Tips - newser.com
Will Mineralys Therapeutics Inc. stock maintain growth story2025 Top Decliners & Fast Gain Swing Trade Alerts - newser.com
What MACD signals say about Mineralys Therapeutics Inc.2025 Short Interest & Fast Gaining Stock Reports - newser.com
A Look at Mineralys Therapeutics's Valuation as Phase 2 EXPLORE-OSA Trial Reaches Enrollment Milestone - simplywall.st
Has Mineralys Therapeutics Inc. formed a bullish divergenceQuarterly Market Summary & Reliable Breakout Forecasts - newser.com
Understanding Mineralys Therapeutics Inc.’s price movementShare Buyback & Real-Time Buy Signal Notifications - newser.com
Mineralys Therapeutics (MLYS) Is Up 10.8% After Completing Phase 2 OSA Trial Enrollment – What's Changed - simplywall.st
Mineralys Therapeutics stock hits all-time high at 41.11 USD By Investing.com - Investing.com Nigeria
Mineralys Therapeutics stock hits all-time high at 41.11 USD - Investing.com
Mineralys Therapeutics (NASDAQ:MLYS) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Published on: 2025-10-10 04:36:23 - newser.com
Is Mineralys Therapeutics Inc. stock reversal real or fakeJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Forecasting Mineralys Therapeutics Inc. price range with options dataTrade Signal Summary & Consistent Profit Trade Alerts - newser.com
EXPLORE-OSA Drug Candidate Trial Fully Enrolled - Sleep Review
Real time breakdown of Mineralys Therapeutics Inc. stock performanceJuly 2025 Levels & Reliable Momentum Entry Alerts - newser.com
Can Mineralys Therapeutics Inc. recover in the next quarterEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Mineralys Therapeutics Inc. stock chart pattern explainedJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Published on: 2025-10-09 03:22:25 - newser.com
Tick level data insight on Mineralys Therapeutics Inc. volatility2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Will Mineralys Therapeutics Inc. see short term momentumJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MSN
What drives Mineralys Therapeutics Inc stock priceEarnings Season Recap & Low Risk Trading Ideas - earlytimes.in
Can swing trading help recover from Mineralys Therapeutics Inc. lossesJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Applying Wyckoff theory to Mineralys Therapeutics Inc. stockWeekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
What’s next for Mineralys Therapeutics Inc. stock priceJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Mineralys Therapeutics Inc.’s volatility index tracking explained2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial - MyChesCo
Is Mineralys Therapeutics Inc. stock poised for growthTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Tools to assess Mineralys Therapeutics Inc.’s risk profileJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
Statistical indicators supporting Mineralys Therapeutics Inc.’s strengthJuly 2025 Action & Community Consensus Stock Picks - newser.com
What does recent volatility data suggest for Mineralys Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Top chart patterns to watch in Mineralys Therapeutics Inc.2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.2%Here's Why - MarketBeat
Could Mineralys Therapeutics (MLYS) Trial Progress Hint at a Broader Hypertension Strategy? - simplywall.st
Mineralys Therapeutics Announces Public Offering of Shares - MSN
uniQure, Dianthus Therapeutics, and Mineralys Therapeutics Lead September 2025 Biotech Funding Rounds - geneonline.com
The biggest biotech funding rounds in September 2025 - Labiotech.eu
Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial - Yahoo Finance
A Fresh Look at Mineralys Therapeutics (MLYS) Valuation Following New Clinical Milestones for Lorundrostat - simplywall.st
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):